Key Highlights

  • 61.4 million USD is the cash, cash equivalents and marketable securities balance Unicycive Therapeutics, Inc. (NASDAQ:UNCY) reported at June 30, 2026, with management expecting its cash runway to extend into 2027.
  • 1.7 million USD is the second quarter 2026 net loss at Unicycive Therapeutics, Inc. (NASDAQ:UNCY), compared with USD 6.4 million a year earlier, or a loss of USD 0.06 per share versus USD 0.52.
  • 8.4 million USD is the other income Unicycive Therapeutics, Inc. (NASDAQ:UNCY) recorded in the second quarter of 2026, driven mainly by a change in the Fair Value of its Warrant liability.
  • 2 complete response letters, in June 2025 and June 2026, have cited the same third-party Manufacturing deficiencies for oxylanthanum carbonate, the lead candidate of Unicycive Therapeutics, Inc. (NASDAQ:UNCY), with no efficacy or safety concerns raised.

What Investors Expect From Unicycive Therapeutics, Inc. (NASDAQ:UNCY) on November 16, 2026

Unicycive Therapeutics is scheduled to report third quarter 2026 results on Monday, November 16, 2026, for the quarter ended September 30, 2026. As a clinical-stage company with no product revenue, investors will focus on operating spending, the cash balance and regulatory progress rather than sales. The comparison period is the third quarter of 2025, when cash stood at USD 42.7 million and the loss was USD 0.13 per share. The second quarter of 2026 showed a loss of USD 0.06 per share on a net loss of USD 1,722 thousand, against USD 6,447 thousand a year earlier.

The Rationale: Last Reported Quarter and Management Outlook for Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

In the quarter ended June 30, 2026, Research and Development expense rose to USD 2.8 million from USD 1.8 million and general and administrative expense rose to USD 7.4 million from USD 5.2 million, together a calculated USD 10.2 million of operating expense. The company attributed the increases to rises of USD 0.9 million and USD 1.4 million in non-cash stock-based compensation, respectively, and USD 0.4 million of commercial launch preparation. The FDA has assigned a Facility inspection to the third-party manufacturer. Chief Executive Officer Shalabh Gupta said the assignment marks a positive step forward and the company expects to resubmit the new drug application once the facility passes inspection.

Valuation, Liquidity and Risks for Unicycive Therapeutics, Inc. (NASDAQ:UNCY)

Liquidity of USD 61.4 million at June 30, 2026 compares with the calculated quarterly Operating Expense of USD 10.2 million, supporting the stated runway into 2027. The reported net loss was narrowed by non-cash warrant fair value gains, so quarterly results can swing with the share price. The company has not stated a PDUFA date. Risks include dependence on a single third-party manufacturer, the outcome of the FDA inspection, further regulatory delay, the need for additional Capital and the uncertainty of a commercial launch in dialysis patients.

Where Things Stand

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) reports on November 16, 2026 with its lead program waiting on a manufacturing inspection rather than new clinical data. The USD 1.7 million second quarter net loss looks modest, but it reflects USD 8.4 million of other income, while operating expenses of USD 10.2 million show the underlying cost base as launch preparation builds. Cash of USD 61.4 million and a runway into 2027 give management time to complete the inspection and resubmit the application for oxylanthanum carbonate. The third quarter release should update the inspection timeline, spending trends and any change to the resubmission plan for patients with chronic kidney disease on dialysis.